1 |
Bg00012 (dmf) |
- |
- |
- |
- |
013 [1] 13 💬 |
2 |
Bg00012 (dmf) (tecfidera®.) |
- |
- |
- |
- |
013 [1] 13 💬 |
3 |
Biologic dmard |
- |
- |
- |
- |
046 [2] 46, 271 💬 |
4 |
Biological dmards |
- |
- |
- |
- |
086 [1] 86 💬 |
5 |
Classic dmards treatment group |
- |
- |
- |
- |
046 [1] 46 💬 |
6 |
Co-medication: synthetic dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
7 |
Conventional dmard combination |
- |
- |
- |
- |
046 [1] 46 💬 |
8 |
Conventional dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
9 |
Conventional synthetic dmard |
- |
- |
- |
- |
046 [1] 46 💬 |
10 |
Desipramine (dmi) |
Desipramine |
[2] D00812 D00812, D07791 D07791 💬 |
SLC6A2 [2] SLC6A2, SLC6A4 💬 |
Serotonergic synapse [2] Serotonergic synapse, Synaptic vesicle cycle |
006 [2] 6 , 17 💬 |
11 |
Dextromethorphan |
Dextromethorphan |
[3] D00848 D00848, D03742 D03742, D03744 D03744 💬 |
GRIN1 [6] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 |
Alcoholism [20] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
002 [11] 2 , 6 , 8 , 13, 21, 46, 78, 85, 96, 97, 156 💬 |
12 |
Dextromethorphan 30 mg |
Dextromethorphan |
[3] D00848 D00848, D03742 D03742, D03744 D03744 💬 |
GRIN1 [6] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 |
Alcoholism [20] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
096 [2] 96, 97 💬 |
13 |
Dextromethorphan and caffeine |
Caffeine |
[5] D00528 D00528, D00848 D00848, D01453 D01453, D03742 D03742, D03744 D03744 💬 |
ADORA1 [17] ADORA1, ADORA2A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, SIGMAR1 💬 |
Alcoholism [37] Alcoholism, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Apelin signaling pathway, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Huntington disease, Insulin signaling pathway, Long-term potentiation, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
078 [1] 78 💬 |
14 |
Dextromethorphan hbr and quinidine sulfate |
Dextromethorphan |
[7] D00642 D00642, D00643 D00643, D00848 D00848, D02272 D02272, D03742 D03742, D03744 D03744, D08458 D08458 💬 |
GRIN1 [11] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 |
Adrenergic signaling in cardiomyocytes [22] Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway |
002 [1] 2 💬 |
15 |
Dextromethorphan hydrobromide |
Dextromethorphan |
[3] D00848 D00848, D03742 D03742, D03744 D03744 💬 |
GRIN1 [6] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 |
Alcoholism [20] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
013 [2] 13, 46 💬 |
16 |
Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg |
Dextromethorphan |
[7] D00642 D00642, D00643 D00643, D00848 D00848, D02272 D02272, D03742 D03742, D03744 D03744, D08458 D08458 💬 |
GRIN1 [11] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 |
Adrenergic signaling in cardiomyocytes [22] Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway |
002 [2] 2 , 13 💬 |
17 |
Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg |
Dextromethorphan |
[7] D00642 D00642, D00643 D00643, D00848 D00848, D02272 D02272, D03742 D03742, D03744 D03744, D08458 D08458 💬 |
GRIN1 [11] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 |
Adrenergic signaling in cardiomyocytes [22] Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway |
002 [2] 2 , 13 💬 |
18 |
Dextromethorphan/quinidine |
Dextromethorphan |
[7] D00642 D00642, D00643 D00643, D00848 D00848, D02272 D02272, D03742 D03742, D03744 D03744, D08458 D08458 💬 |
GRIN1 [11] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 |
Adrenergic signaling in cardiomyocytes [22] Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway |
013 [1] 13 💬 |
19 |
Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg) |
Dextromethorphan |
[7] D00642 D00642, D00643 D00643, D00848 D00848, D02272 D02272, D03742 D03742, D03744 D03744, D08458 D08458 💬 |
GRIN1 [11] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 |
Adrenergic signaling in cardiomyocytes [22] Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway |
008 [1] 8 💬 |
20 |
Diagnostic test: dm1-activc |
- |
- |
- |
- |
113 [1] 113 💬 |
21 |
Dimebon + dextromethorphan |
Dextromethorphan |
[4] D00848 D00848, D03742 D03742, D03744 D03744, D09917 D09917 💬 |
ACHE [7] ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 |
Alcoholism [22] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
008 [1] 8 💬 |
22 |
Dimethyl fumarate (dmf) |
Dimethyl fumarate |
[1] D03846 D03846 💬 |
KEAP1 [1] KEAP1 💬 |
Fluid shear stress and atherosclerosis [4] Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
013 [3] 13, 51, 86 💬 |
23 |
Dimethyl fumarate [dmf] |
Dimethyl fumarate |
[1] D03846 D03846 💬 |
KEAP1 [1] KEAP1 💬 |
Fluid shear stress and atherosclerosis [4] Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
013 [1] 13 💬 |
24 |
Disease-modifying antirheumatic drugs (dmards) |
- |
- |
- |
- |
046 [1] 46 💬 |
25 |
Dm |
- |
- |
- |
- |
006 [2] 6 , 8 💬 |
26 |
Dm-1992 |
- |
- |
- |
- |
006 [1] 6 💬 |
27 |
Dmard |
- |
- |
- |
- |
046 [1] 46 💬 |
28 |
Dmard cessation |
- |
- |
- |
- |
046 [1] 46 💬 |
29 |
Dmard maintenance |
- |
- |
- |
- |
046 [1] 46 💬 |
30 |
Dmard therapy |
- |
- |
- |
- |
046 [1] 46 💬 |
31 |
Dmards |
- |
- |
- |
- |
046 [2] 46, 271 💬 |
32 |
Dmards (disease-modifying antirheumatic drugs) |
- |
- |
- |
- |
046 [1] 46 💬 |
33 |
Dmards (methotrexate |
Methotrexate |
[2] D00142 D00142, D02115 D02115 💬 |
DHFR [2] DHFR, DHFR2 💬 |
Antifolate resistance [5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 [1] 46 💬 |
34 |
Dmards or biologics |
- |
- |
- |
- |
046 [1] 46 💬 |
35 |
Dmi |
- |
- |
- |
- |
006 [2] 6 , 17 💬 |
36 |
Dmps |
2,3-Dimercapto-1-propanesulfonic acid |
- |
- |
- |
171 [1] 171 💬 |
37 |
Dmsa |
Succimer |
[1] D00572 D00572 💬 |
- |
- |
171 [1] 171 💬 |
38 |
Dmso |
Dimethyl sulfoxide |
[1] D01043 D01043 💬 |
- |
- |
226 [1] 226 💬 |
39 |
Dmso cocktail |
Dimethyl sulfoxide |
[1] D01043 D01043 💬 |
- |
- |
226 [1] 226 💬 |
40 |
Dmt |
- |
- |
- |
- |
013 [1] 13 💬 |
41 |
Dmt continuation |
- |
- |
- |
- |
013 [1] 13 💬 |
42 |
Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc |
Etanercept |
[1] D00742 D00742 💬 |
LTA [2] LTA, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 [1] 46 💬 |
43 |
Exposure to one or more disease-modifying drug(s)(dmds) used to treat ms |
- |
- |
- |
- |
013 [1] 13 💬 |
44 |
Huc-msc + dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
45 |
Injectable ms dmt |
- |
- |
- |
- |
013 [1] 13 💬 |
46 |
Ionis-dmpkrx |
- |
- |
- |
- |
113 [1] 113 💬 |
47 |
Non-biologic disease modifying anti-rheumatic drug (dmard) |
- |
- |
- |
- |
046 [1] 46 💬 |
48 |
Non-biologic dmards |
- |
- |
- |
- |
046 [2] 46, 86 💬 |
49 |
Non-biological dmard's |
- |
- |
- |
- |
046 [1] 46 💬 |
50 |
Non-biological dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
51 |
Nonbiologic dmards of investigator's choice |
- |
- |
- |
- |
046 [1] 46 💬 |
52 |
Other dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
53 |
Other: dmt withdrawal |
- |
- |
- |
- |
013 [1] 13 💬 |
54 |
Other: group 2 (dmards treated group) |
- |
- |
- |
- |
046 [1] 46 💬 |
55 |
Other: other: disease modifying therapies (dmt) |
- |
- |
- |
- |
013 [1] 13 💬 |
56 |
Patient treated with dmard |
- |
- |
- |
- |
046 [1] 46 💬 |
57 |
Permitted dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
58 |
Phase 1: conventiaonal dmard |
- |
- |
- |
- |
046 [1] 46 💬 |
59 |
Rheumatoid arthritis with disease-modifying drugs (dmards) |
- |
- |
- |
- |
046 [1] 46 💬 |
60 |
Standard dmards (disease modifying anti rheumatic drugs) |
- |
- |
- |
- |
046 [1] 46 💬 |
61 |
Standard ms dmt |
- |
- |
- |
- |
013 [1] 13 💬 |
62 |
Standard ms dmts |
- |
- |
- |
- |
013 [1] 13 💬 |
63 |
Synthetic dmard(s) |
- |
- |
- |
- |
046 [1] 46 💬 |
64 |
Therapy with disease-modifying anti rheumatic drugs (dmard) |
- |
- |
- |
- |
046 [1] 46 💬 |
65 |
Tnf-a antagonists, non-tnfs, dmard non-biologics |
- |
- |
- |
- |
046 [2] 46, 271 💬 |
66 |
Uc-msc+dmards |
- |
- |
- |
- |
046 [1] 46 💬 |